Dr. Wozniak on Optimizing the Use of Immunotherapy in NSCLC

Supplements And Featured PublicationsThe Evolving Role of Immunotherapy in Metastatic Non–Small Cell Lung Cancer
Volume 1
Issue 1

Antoinette Wozniak, MD, FACP, FASCO, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer.

Antoinette Wozniak, MD, FACP, FASCO, a visiting professor of medicine and associate director of clinical research at the University of Pittsburgh Medical Center (UPMC), as well as the director of the Lung Cancer Disease Unit and co-director of the UPMC Lung Cancer Center of Excellence, discusses optimizing the use of immunotherapy in patients with non–small cell lung cancer (NSCLC).

Many ongoing research efforts are examining which patients are most likely to benefit from immunotherapy, according to Wozniak. This is important, as many patients with NSCLC who are treated with this modality may not achieve clinical benefit, Wozniak says.

Another area of focus is identifying why some patients do not respond to treatment, or stop responding entirely, as well as whether utilizing 2 immunotherapy agents that target 2 different pathways will be useful in overcoming mechanisms of resistance or acquired resistance. The field hopes to answer these questions in the coming years, Wozniak concludes.

Related Videos
Joshua K. Sabari, MD, an expert on lung cancer, presenting slides
Chul Kim, MD, MPH
Salman R. Punekar, MD, Mayo Clinic
Federico Cappuzzo, MD
Pasi A. Jänne, MD, PhD, director, Lowe Center for Thoracic Oncology, director, Belfer Center for Applied Cancer Science, director, Chen-Huang Center for EGFR Mutant Lung Cancers, senior physician, David M. Livingston, MD, Chair, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Edgardo S. Santos Castillero, MD, FACP
Joshua K. Sabari, MD
Coral Olazagasti, MD